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Malaria may be a serious complication of blood transfusion due to the asymptomatic persistence of parasites in
some donors. This case report highlights the transfusion-transmitted malaria of Plasmodium vivax in a child
diagnosed with germ cell tumour. This child had received blood transfusion from three donors and a week later
started developing malaria like symptoms. Nested PCR and sequencing confirmed that one of the three donors was
infected with P. vivax and this was transmitted to the 12-year-old child. To the best of the authors’ knowledge, this
is the first reported transfusion-transmitted malaria case in Malaysia.
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Although transfusion therapy aids in saving lives, blood
can serve as a means to transmit infections, including
parasitic infections [1]. Although the incidence of blood
transfusion-transmitted parasitic infections (TTPI) is ad-
mittedly lower compared to viral and bacterial infections,
it is important to understand that parasites can cause ail-
ment, especially in immunocompromised individuals [2]
Transfusion-transmitted malaria (TTM) occurs when the
patient is infected by the same parasite that was present in
the donor’s blood. TTM was first reported in 1911 [2-4].
While parasitic infections transmitted via accidental ex-
posure to infected blood or blood transfusion may occa-
sionally be difficult to diagnose in regions/areas where
these infections are not endemic, such is usually not the
case. TTM is in fact much harder to be identified in en-
demic countries as majority of donors may be potentially
infected with malaria parasites [3]. Precise data on the in-
cidence of TTM are under-reported in malaria-endemic
areas, where recipients are known to have pre-existing
infection. In non-endemic regions, the reported inci-
dences range from zero to two cases per million dona-
tions [5]. As far as the authors are concerned, this is the* Correspondence: lauyeeling@um.edu.my
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reported in Malaysia.Case presentation
A 12-year-old Chinese male child diagnosed with intra-
cranial malignant germ cell tumour received packed red
cell transfusions at the University Malaya Medical Centre
(UMMC), Malaysia in August 2012 for chemotherapy-
induced anaemia. He received blood from three donors: a
Myanmarese male and two Malaysian donors. A week later,
upon returning to his home state, the patient started deve-
loping malaria-like symptoms. He sought consultation at
the local hospital and was diagnosed with malaria following
a blood test. He then returned to UMMC for further treat-
ment. Blood samples from the patient and the three donors
were sent to the Department of Parasitology, Faculty of
Medicine, University of Malaya for further testing.
Giemsa-stained (5%) blood smear from the patient was
prepared and examined under light microscope. Exami-
nation of the slide was carried out by a skilled microscop-
ist and visualization of the blood smear showed a 0.03%
parasitaemia P. vivax infection. Polymerase chain reaction
(PCR) was carried out on the blood samples of the patient
and the three donors to confirm the species of the malaria
parasite. DNA was extracted from 100 μl of whole blood
from the patient and the three donors using the DNeasy
Blood & Tissue Kit (QIAGEN, Valencia, CA, USA). Nested
PCR was performed based on the amplification of theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Agarose gel image of patient and donor. Lane 1 is the
100 bp marker. Lanes 2 and 3 are the amplification of both patient
and donor DNA respectively with P. vivax species-specific primer. It is
observed that both individuals show and amplification size on
120 bp, indicating P. vivax infection. Lane 4 is the negative control of
the PCR run with the species-specific primer. Lanes 5 and 6 are the
amplification of both patient and donor DNA respectively with the
genus-specific primer. It is observed that they both indicate a size of
240 bp. Lane 7 is the negative control of the PCR run with the
genus-specific primer.
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viously [6]. The nest 1 reaction mixture of 25 μl contained
4 μl of DNA template, 5 pmol of nest 1 genus-specific
primers (rPLU1: 5′-TCA AAG ATTAAG CCA TGC AAG
TGA-3′and rPLU5: 5′-CCT GTT GTT GCC TTA AAC
TCC-3′), 1× PCR buffer (35 mM Tris–HCl, pH 9.0,
3.5 mMMgCl2, 25 mM KCl, 0.01% gelatine), 0.25 M dNTP,
1 u Taq polymerase and 15.3 μl of nuclease free water. The
nest 1 amplification conditions were as follows: 1) initial de-
naturation at 94°C for 4 min, 2) 35 cycles of denaturation at
94°C for 30 sec, annealing at 55°C for 1 min and extension
at 72°C for 1 min, 3) final extension at 72°C for 10 min and
a hold temperature of 4°C. Each of the nest 2 amplification
mixture of 25 μl contained 4 μl of the nest 1 product and
same amounts of buffer, dNTP, Taq polymerase and nucle-
ase free water as in nest 1. The primer sets used in nest 2
were as follows: (rPLU3: 5′-TTT TTA TAA GGA TAA
CTA CGG AAA AGC TGT-3′and rPLU4: 5′-TAC CCG
TCA TAG CCA TGT TAG GCC AAT ACC-3′) for genus
specific identification, FAL1: 5′-TTA AAC TGG TTT
GGG AAA ACC AAA TAT ATT-3′ and FAL2: 5′-ACA
CAA TGA ACT CAA TCA TGA CTA CCC GTC-3′ for
Plasmodium falciparum, VIV1: 5′-CGC TTC TAG CTT
AAT CCA CAT AAC TGA TAC-3′ and V1V2: 5′-ACT
TCC AAG CCG AAG CAA AGA AAG TCC TTA-3′ for
P. vivax, OVAL1: 5′-ATC TCT TTT GCTATC TTT TTT
TAG TAT TGG AGA- 3′ and OVAL2: 5′-GGA AAA
GGA CAC ATTAAT TGTATC CTA GTG-3′ for Plasmo-
dium ovale, MAL1: 5′-ATA ACA TAG TTG TAC GTT
AAG AAT AAC CGC-3′ and MAL2: 5′-AAA ATT CCC
ATG CAT AAA AAA TTA TAC AAA- 3′ for Plasmodium
malariae, Pmk8: 5′-GTT AGC GAG AGC CAC AAA
AAA GCG AAT-3′ and Pmkr9: 5′-ACT CAA AGT AAC
AAA ATC TTC CGT A-3′ for Plasmodium knowlesi. The
nest 2 cycling conditions were identical to that of nest 1
except that an annealing temperature of 58°C was used
for the species-specific primers. The PCR products were
purified with QIAquick Gel Extraction Kit (QIAGEN,
Valencia, CA, USA) and cloned into pGEM-T Vector Sys-
tems (Promega, Wisconsin, USA) prior to DNA sequen-
cing. Ethical approval for this study was obtained from the
Medical Ethics Committee of University Malaya Medical
Centre (Reference no: 817.18).
Based on the PCR results, it was confirmed that the
Myanmarese male donor was infected with P. vivax and
the other two donors were found to be negative for malaria.
The 26-year-old donor is from Sagaing Region, Myanmar
and first came to Malaysia in 2008 and worked until June
2011 in Semenyih, Selangor. He then returned to Myanmar
for four months and resumed working in Semenyih from
October 2011 till today. The medical history of the donor
did not suggest prior malaria infection nor was there other
significant medical or surgical history. There was no prior
history of receiving blood transfusion either. He firstdonated blood on 1 July, 2012 at a mobile blood campaign
organized by UMMC in Kuala Lumpur. The donor was
examined via microscopy during the donation but no
parasites were detected.
An amplification size of 120 bp was observed for both
the patient and the Myanmarese donor DNA samples
(Figure 1). Sequence alignment studies using Clustal W
2.1 revealed that the two sequences from both indivi-
duals were exactly the same (Figure 2).
Discussion
While malaria is endemic throughout most of the tropics,
transmission of malaria is an unusual event in a non-
endemic area. However, transmission is possible under
certain circumstances such as (i) transmission by local
competent mosquito vectors (ii) being infected by infective
mosquitoes, that travelled aboard an airplane or within
pieces of baggage to non-endemic areas (iii) nosocomial
transmission, which involves a single incident of transmis-
sion to individual patients or hospital staff by blood transfu-
sions, contingent needle-stick injuries or organ transplants
[7,8]. In this report, transmission of malaria via blood trans-
fusion between the patient and donor based on molecular
investigations has been demonstrated.
Figure 2 Sequence alignment of patient and donor sequences. It is observed that both patient and donor sequences are exactly the same.
DG2 represents the genus sequence of the donor while PG2 represents the genus sequence of the patient.
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sion, parasites must circulate in the blood stream of do-
nors, show certain physical characteristics and be able to
survive conservation [2,9]. Such is the case with symptom-
atic malaria donors. In asymptomatic malaria donors how-
ever, the lack of clinical manifestations and subpatent level
of parasites makes diagnosing the infection a difficulty
[10]. Malaria presents itself as a febrile haemolytic disease
that poses a greater threat to pregnant, asplenic or im-
munosuppressed patients [11]. It is a known fact that all
four human malaria parasites (P. falciparum, P. vivax, P.
ovale, and P. malariae) may be transfusion-transmitted
[12]. After the first report in 1911, P. vivax was the pre-
dominant species until the 1950s when P. malariae re-
placed it as the most common causative agent [5]. In the
1970s, P. vivax was again the most common, followed by
P. malariae and P. falciparum. An increasing number of
transfusion-transmitted P. falciparum cases were observed
at the same time with a high mortality rate [13]. In the past
decade or so, several transfusion-transmitted malaria cases
have been reported in Brazil [14,15], France [16], Republic
of Korea [17], Colombia [18], USA [19] and UK [20].
Any blood component containing erythrocytes can
harbour viable parasites. Whole blood and red blood cell
(RBC) represent the most common sources of TTM.
However, cases involving leukocytes, platelets, fresh frozen
plasma, and frozen RBCs have been previously reported
[5,14]. In both malaria-endemic and non-endemic countries,
TTM can be a problem due to several characteristics of mal-
aria infection: (a) partially immune individuals with low level
parasitaemia remain asymptomatic and can qualify as blood
donors; (b) Plasmodium is able to survive in blood stored at
4°C; and, (c) the sensitivity of the methods currently in use
for detection of malaria is much lower than that required to
detect level of parasitaemia capable of causing TTM [14,21].
In this case, it is possible that examination might have been
performed by a non-expert who overlooked the donor as a
potential threat due to sub-patent parasitaemia count. While
blood safety remains an issue of great concern in transfusionmedicine in all countries, it is of greater concern in develo-
ping countries where blood transfusion policies, trained
personnel, appropriate infrastructure and financial resources
are lacking or inadequate [1].
The donor, as previously mentioned, is from Sagaing
Division, Myanmar. This location is situated in the
north-west of Myanmar between Chin State on the west,
Kachin State on the north-east, Shan State on the east and
Magway Division and Mandalay Division on the south. Mal-
aria is a major health issue in Myanmar, where resistant P.
falciparum has already emerged [22]. Myanmar records an
estimated 4.2 million cases annually and 69% of its popula-
tion lives in malaria-endemic areas. Myanmar accounts for
75% of malaria cases and fatalities in the Mekong region
and drug resistant malaria poses a greater threat [23]. In
Sagaing Division, malaria cases are more prevalent in the
months of June through November. These cases are pre-
dominantly due to P. falciparum but there are cases that
are attributed to P. vivax as well [24]. In 2008, this division
recorded an alarming 116,080 malaria cases, which placed
it in second position from a list of 17 tested states/divi-
sions [25]. It is an established fact that repeated exposure
to malaria infection enables individuals to be protected
against the disease as they would have progressively ac-
quired antiparasite immunity [26]. Acquired semi-immunity
could very well be the scenario with the donor as he comes
from a region where transmission levels are high. Following
an attack of malaria, a donor may remain infective for a
long period of time, i.e., one to three years in P. falciparum,
three to four years in P. vivax and for as long as 50 years in
P. malariae [27].
Measures to monitor and assess transfusion transmission
of infection, associating this to donor risk and evaluating
possible threats to safety are pertinent [28]. There are two
pivotal aspects to consider when taking into account malaria
risk and transfusion: first, identification of malaria risk do-
nors and second, managing the risk donors by either deferral
or screening (including information of travel history and pre-
vious infection) [2,3]. A recent International Forum showed
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tionnaire is known to be the major deciding factor in pre-
vention of transfusion-associated protozoan diseases [29].
It has been noted that most of the non-endemic countries
follow the rule of donor deferral for 3 years after a donor
has been infected with malaria [29]. While the develop-
ment of donor-deferral guidelines that are appropriate to
the country and to the donor population is of utmost im-
portance to donor screening, one must bear in mind that
complete prevention of TTM may not be possible [4]. In
non-endemic countries, risk of transmission is minimized
through donor deferral together with specific antimalarial
antibody screening. In endemic countries however, more
thorough donor questioning is required. This is coupled with
knowledge of geographical distribution and seasonal vari-
ation to aid the identification of possibly infected donors [3].
A recent publication indicated that although malaria para-
sites are commonly found in the blood of donors in malaria-
endemic areas, TTM does not occur frequently [30].
Before blood donation, the donor is required to fill out
a consent and assessment form. Based on standard pro-
cedures, prior transfusion, a donor’s blood is subject to
two tests. The first being the ABO blood group test and
the second is a virology test, whereby the donor’s blood
is screened for HIV, hepatitis B, hepatitis C and syphilis.
In the rare event there are donors from malaria endemic
countries, microscopic examination is performed to iden-
tify donors who may be potentially infected.
Conclusion
Although no set of guidelines is flawless, appropriate defer-
ral strategies coupled with appropriate laboratory screening
will reduce the risk of TTM to a minimum. Donor selec-
tion is particularly difficult in healthy asymptomatic adults
as they do not have fever and questionnaires do not iden-
tify such donors. However, with more rigorous questioning,
there is a possibility of overcoming this problem. The
in vitro processing of donor blood with antimalarials to kill
parasites prior transfusion is also another measure to pre-
vent TTM. In this study, the authors report a P. vivax
transfusion-transmitted case which to the best of the authors’
knowledge is the first reported incident in Malaysia.
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